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Surgery for Severe Ischemic Mitral Regurgitation
To the Editor: In 2009, Magne et al.1 summa-
rized numerous studies showing that simple ring 
repair of severe ischemic regurgitation associ-
ated with moderate or severe tethering would 
prematurely fail. They concluded that compre-
hensive imaging was necessary to tailor the in-
tervention to the individual patient. Subsequent-
ly, a multi-institutional laboratory trial showed 
that more complex annular and subvalvular re-
pair was required to optimize remodeling and 
prevent recurrent regurgitation.2 Complex repair 
is also supported clinically.3,4
Nonetheless, Acker et al. (Jan. 2 issue)5 used 
a simple ring for all repairs, even though tether-
ing was required for enrollment. Mitral interven-
tion was guided solely by regurgitant grade. 
Conducting a blind, randomized trial in which 
all patients with ischemic regurgitation were 
assigned to simple ring repair or replacement is 
akin to randomly assigning all patients with 
lung cancer to lobectomy or pneumonectomy, 
regardless of the stage of disease. The trial does 
not support the authors’ conclusion that replace-
ment is superior to repair. They simply reaffirm 
that simple ring repairs fail when moderate or 
severe tethering is present.
Axial echocardiography greatly facilitates the 
stratification of disease severity and the identifi-
cation of the individualized techniques required 
to optimize remodeling, provide freedom from 
recurrence, and increase the likelihood of sur-
vival (Fig. 1).4 Detailed image guidance is essen-
tial to achieve the best possible results.
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Figure 1. Axial Echocardiographic Stratification of Severity of Ischemic 
Distortion and Identification of the Most Effective Approach to Repair.
Spearman’s rank-correlation coefficients (rs) were used to evaluate proce-
dural complexity in relation to tenting area (rs, 0.833) and leaflet bending 
(rs, −0.821) (P<0.05 for both comparisons) (Panel A). Both tenting (bor-
dered by leaflets and the plane of the annulus) and leaflet bending (the 
angle between the proximal and distal anterior leaflet) were measured in a 
long-axis view. A circle indicates simple-ring annuloplasty, an x additional 
subvalvular repair, and a plus sign anterior-leaflet augmentation combined 
with simple-ring annuloplasty and subvalvular repair. Kaplan–Meier esti-
mates are shown (Panel B). MR denotes mitral regurgitation.
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To the Editor: Acker et al. report no significant 
difference between mitral-valve annuloplasty and 
replacement regarding left ventricular reverse re-
modeling and 12-month survival in patients with 
severe ischemic mitral regurgitation, which was 
defined as an effective regurgitant orifice of 
more than 40 mm2. However, because of the often 
hemielliptical shape of the mitral-regurgitation 
convergence zone, its use may lead to underesti-
mation of the severity of mitral regurgitation. 
Severe ischemic mitral regurgitation should be 
considered when the effective regurgitant orifice 
is greater than 20 mm2. Consequently, a large 
number of patients probably had massive mitral 
regurgitation, limiting the potential effects of 
mitral-valve annuloplasty. When the effective re-
gurgitant orifice was not quantifiable, severe mi-
tral regurgitation was defined according to an 
integrative approach that included the ratio of jet 
area to the left atrial area, which is no longer 
recommended,1 or an approach that relied on 
vena contracta jet width without a specified cut-
off value.
 The authors do not mention the extent of the 
undersizing (i.e., one or two sizes) when they de-
scribe the mitral-valve annuloplasty procedure. 
Furthermore, to be effective, annuloplasty should 
target a leaflet-coaptation width of 8 mm or 
more.2 Although mitral-valve annuloplasty is not 
necessarily the best possible surgical approach 
for patients with ischemic mitral regurgitation, 
the results of the present study need to be inter-
preted carefully.
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To the Editor: Acker et al., reporting for the 
Cardiothoracic Surgical Trials Network, describe 
the results of a multicenter, randomized trial to 
evaluate the relative benefits and risks of valve 
repair versus replacement in patients with severe 
ischemic mitral regurgitation. No significant dif-
ference between the treatment groups was ob-
served in left ventricular volume or survival at 12 
months. However, whereas significant recurrent 
ischemic mitral regurgitation developed in more 
than 30% of the patients in the repair group, the 
patients in this group who did not have recurrent 
ischemic mitral regurgitation realized a 22.6% 
reduction in left ventricular volume versus a 6.8% 
reduction in the valve-replacement group. These 
data suggest a large potential benefit of valve re-
pair if the effects of recurrent ischemic mitral 
regurgitation can be limited. The maturation of 
percutaneous valve-replacement technology that 
has occurred since the study’s inception offers 
the potential for a new therapeutic model for 
these high-risk patients: all such patients should 
receive surgical annuloplasty, with recurrent is-
chemic mitral regurgitation treated with percu-
taneous valve-in-ring procedures.1-3 This clinical 
strategy would maximize the beneficial effects 
of repair, eliminate the early morbidity associat-
ed with replacement, and neutralize the effects 
of recurrent ischemic mitral regurgitation.
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The Authors Reply: The primary aim of our 
trial was to compare the most common mitral-
valve repair procedure performed worldwide for 
severe ischemic mitral regurgitation (which in-
volves placement of an undersized annuloplasty 
ring) with chord-sparing valve replacement. Con-
trary to the comments of Drake et al., a subvalvu-
lar procedure for severe tethering was a protocol-
defined surgical option. Moreover, our conclusion 
was not that replacement is better than repair but 
rather that both methods are equivalent in de-
gree of reverse remodeling, adverse events, qual-
ity of life, and survival at 1 year. The repair group 
had a 32% incidence of recurrent moderate-to-
severe mitral regurgitation, which is consistent 
with the published literature. The planned 2-year 
follow-up should offer further insights into the 
effects of recurrent mitral regurgitation. As 
Drake et al. point out, although there is limited 
and preliminary experience with the use of teth-
ering to guide mitral-valve repair and the sever-
ing of chords as an adjunct to mitral-valve ring 
annuloplasty, these approaches are less well vali-
dated than simple ring repair. Planned subanaly-
ses will help determine the echocardiographic 
and clinical measures that predict recurrence.
Magne and Pierard advocate defining severe 
ischemic mitral regurgitation as an effective 
regurgitant orifice area of 0.2 cm2 rather than 
0.4 cm2. We used the integrated approach to 
grade severe mitral regurgitation that is recom-
mended in valve guidelines by both the American 
College of Cardiology–American Heart Associa-
tion and the European Society of Cardiology.1,2 
This approach incorporates multiple variables 
without overreliance on a single measure. The 
mean effective regurgitant orifice areas for the 
treatment groups were 0.39 cm2 and 0.40 cm2, 
which appropriately reflect a lower range for ef-
fective regurgitant orifice area for ischemic mi-
tral regurgitation. Moreover, the average ring size 
used in our trial was 28.4±1.9 mm for men and 
27.2±1.6 mm for women, indicating that there 
was substantial undersizing, with more than 
90% of patients in the repair group receiving a 
complete ring.
Gorman et al. point out that there was sub-
stantial reverse remodeling among the patients 
in the repair group who did not have recurrent 
moderate or severe mitral regurgitation (a 22.6% 
reduction in left ventricular volume, vs. 6.8% in 
the replacement group). They propose that all 
patients should undergo repair and that those in 
whom postoperative moderate or severe mitral 
regurgitation develops (32% in our study) should 
undergo secondary percutaneous mitral-valve re-
placement. A less speculative and less aggressive 
approach would be to use predictive models of 
recurrent mitral regurgitation and, in patients 
with a high likelihood of recurrence, to use re-
placement or a more complex repair technique 
that specifically addresses leaflet tethering. Our 
trial clearly shows that mitral-valve replacement 
with complete chordal sparing is an acceptable 
and safe treatment option in patients with severe 
ischemic mitral regurgitation.
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Increase in Left Ventricular Assist Device Thrombosis
To the Editor: The number of implantations of 
left ventricular assist devices (LVADs) is greatly 
increasing worldwide, and the article by Starling 
et al. (Jan. 2 issue)1 is of major interest in the 
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